Pular para o conteúdo principal
Ranking Invest

MRUS - Merus N.V.

Segmento: HealthcareMerus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Dados da Empresa

Patrimônio Líquido

$ 596.12 Mi

Dívida Líquida

-$ 195.43 Mi

L4T

-$ 277.34 Mi

MM4T

-558.43%

Indicadores Básicos

ROE

-46.52%

Índices de Previsibilidade

Receita Líquida

E0.14

Lucro

C0.45

Margem

C0.46

Índices de Tendência

Receita Líquida

E-7.39

Lucro

F-7.63

Margem

F-6.94

Índices de Endividamento

DIV/PAT

-0.33

DIV/L4T

0.70

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.